CONTAINER ASSEMBLIES FOR CONTAINING AND DELIVERING MEDICAMENTS, AND METHODS OF FILLING SUCH ASSEMBLIES
20230270935 · 2023-08-31
Inventors
- Alex LYNESS (West Chester, PA, US)
- Menaka Abeygunawardena (Blue Bell, PA, US)
- Lawton Laurence (Chester Springs, PA, US)
- Christian EICHHORN (Pottstown, PA, US)
- Samuel Molina (Lansdale, PA, US)
Cpc classification
A61M5/283
HUMAN NECESSITIES
A61M5/31513
HUMAN NECESSITIES
A61M5/14566
HUMAN NECESSITIES
International classification
Abstract
A container assembly for containing and delivering a medicament is described. The container assembly includes a container having a first end and a second end. The first end includes an opening, and a plunger assembly at least partially disposed in the container. The plunger assembly includes a main body and at least one resilient portion at least partially retained by a groove in the main body. The resilient portion forms a seal with the container. The plunger assembly forms a temperature resilient seal with the container such that the container assembly is operable to contain a medicament between the seal and the opening at: (a) room temperature, and (b) during freeze storage of the medicament. The plunger assembly is moveable relative to the container at room temperature.
Claims
1. A container assembly for containing and delivering a medicament, the container assembly comprising: a container having a first end and a second end, the first end comprising a first opening; and a plunger assembly at least partially disposed in the container, the plunger assembly comprising: a main body; and at least one resilient portion at least partially retained by a groove in the main body and forming a seal with the container, wherein the plunger assembly is configured to: form a temperature resilient seal with the container such that the container assembly is operable to: contain a medicament between the seal and the first opening at: (a) room-temperature and (b) during freeze storage of the medicament; and be moveable relative to the container at room temperature.
2. The container assembly of claim 1, wherein the plunger assembly is configured to be moved relative to the container by a drive element.
3. The container assembly of claim 1, wherein the resilient portion is configured to provide an interference fit with the container.
4. The container assembly of claim 1, wherein the at least one resilient portion comprises a core and a jacket, the jacket at least partially encapsulating the core.
5. The container assembly of claim 4, wherein the jacket comprises a fluoropolymer material.
6. The container assembly of claim 1, wherein the at least one resilient portion is an encapsulated O-ring.
7. The container assembly of claim 1, wherein the at least one resilient portion comprises a spring energised seal, and wherein the spring energised seal comprises a spring and a sealing ring.
8. The container assembly of claim 7, wherein the spring is a continuous contact spring, a cantilever spring, a helical-wound spring, or an elliptical coil spring.
9. The container assembly of claim 7, wherein the sealing ring comprises a fluoropolymer material.
10. The container assembly of claim 1, wherein the plunger assembly comprises at least two resilient portions, and wherein: one of the at least two resilient portions is configured to form the temperature resilient seal; and the other of the at least two resilient portions is configured to stabilize the plunger assembly in the container.
11. The container assembly of claim 1, wherein room temperature is around 20° C. and the freeze storage of the medicament is carried out at −50° C. to −200° C.
12. The container assembly of claim 1, wherein freeze storage of the medicament is carried out at cryogenic or at ultralow temperatures.
13. The container assembly of claim 1, further comprising a stopper assembly configured to seal the first opening, the stopper assembly comprising: a stopper at least partially disposed in the opening of the container; and at least one resilient sealing portion at least partially retained by the stopper and forming a seal with the container.
14. The container assembly of claim 13, further comprising a first end cap configured to maintain the stopper in position at least partially within the first opening of the container.
15. The container assembly of claim 1, further comprising an insert at least partially disposed in the container, the insert being configured to maintain a minimum distance between the plunger assembly and the second end of the container.
16. The container assembly of claim 15, further comprising a second end cap configured to engage the container and retain the insert in the container.
17. The container assembly of claim 1, further comprising a vented end cap configured to engage the container at or near the second end of the container, and wherein: the second end comprises a second opening; and the vented end cap comprises one or more openings configured to allow air to pass into or out of the container through the second opening.
18. The container assembly of claim 1, further comprising a one-way check valve at least partially disposed at or near the first end of the container, the one-way check valve configured to allow fluid flow into the container via the first opening.
19. The container assembly of claim 18, further comprising a valve cover configured to engage the container at or near the first end of the container to protect the one-way check valve.
20. The container assembly of claim 18, further comprising a valve adaptor configured to engage the container at or near the first end of the container, the valve adapter configured to open the one-way check valve and allow fluid flow out of the container.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0063] The invention will now be described in more detail with reference to a number of non-limiting, exemplary embodiments shown in the following drawings, in which:
[0064]
[0065]
[0066]
[0067]
[0068]
[0069]
[0070]
[0071]
[0072]
[0073]
[0074]
[0075]
[0076]
[0077]
[0078]
[0079]
[0080]
[0081]
[0082]
[0083]
[0084]
[0085]
[0086]
[0087]
[0088]
[0089]
[0090]
[0091]
[0092] Like reference numerals are used for like components throughout the drawings.
DETAILED DESCRIPTION
[0093] The present disclosure is directed generally to a plunger for a container assembly, a container assembly comprising a plunger, and associated methods for manufacturing and using container assemblies according to the disclosure. The plunger assembly and container assemblies incorporating it are generally well suited to maintaining a seal at very low temperatures (e.g., medicaments stored at ultralow or cryogenic temperatures), whilst still being manually slidable within a container body at room temperatures.
[0094]
[0095] The container can be made of a glass or polymeric material. In at least one configuration, the container 102 comprises a clear plastic material, such as cyclic olefin polymer (COP), cyclic olefin copolymer (COC) and/or polypropylene (PP). Container bodies suitable for use in assemblies according to the present disclosure may be formed by injection moulding or blow moulding.
[0096] The container assembly 100 further comprises a plunger assembly 106. The plunger assembly 106 is configured to be seated at least partially within the internal volume of the container 102 and to form a seal with an inner surface of the generally cylindrical container body 102. The plunger assembly 106 is also configured to be moved relative to the container 102 by a plunger rod (shown in
[0097] Referring now to
[0098] The main body 108 may be formed of an elastomeric material, for example: rubbers, halogenated butyl rubbers, silicon rubbers, isoprene rubbers, and Styrene butadiene rubbers. Alternatively, the main body 108 can comprise a rigid polymer, such as a fluoropolymer (including one or more of PTFE, PCTFE, FEP) or a clear plastic material (including one or more of COP, COC, PP). In a preferred embodiment, at least one of the top surface or bottom surface of the main body is laminated with an inert film, most preferably the surface of the main body 108 that will contact the medicament stored within the container. Examples of inert films include, but are not limited to, fluorinated polymers, such as ETFE, PTFE, FEP and monolayer polyolefin films such as COP, COC, and PE. The main body 108 may be a monolithic component, i.e., formed as a single piece. The main body 108 can be an injection-moulded, compression moulded, or machined.
[0099] The main body 108 of the plunger assembly 106 can be made from a material that has similar or equivalent thermal expansion properties as the container 102 such as plastic materials (including one or more of COP, COC, PP) to ensure consistent expansion and contraction between the plunger assembly 106 and the container 102.
[0100] Referring now to
[0101] The distance d1 can be less than a thickness (measured in a radial direction) of the resilient portion 110. In this way, the groove 112 can be configured to partially receive the resilient portion 110 so that the outer surface of the resilient portion 110 extends beyond at least a portion of the outer surface of the main body 108 by a distance d2. This ensures that the resilient portion 110 provides a sealing surface for contacting an inner surface of the container 102. In this way, the resilient portion 110 can be configured to provide an interference fit with the container 102. In at least some configurations, it is preferred that the sealing surface(s) provided by the resilient portion(s) have an outer diameter that is approximately equal to an outer diameter of a leading portion of the plunger. For example, the main body of the plunger may have a shape similar to that described in U.S. Pat. No. 10,258,744. In such a configuration, the resilient portion(s) 110 take the place of (or are provided in addition to) the ribs of the plunger described in U.S. Pat. No. 10,258,744.
[0102] Although the configuration shown in
[0103] As shown in
[0104] Referring to
[0105] The jacket 110b′, which partially or wholly encapsulates the core 110a′, can comprise an inert material (compatible with drug products) and/or one that can provide low frictional engagement with the inner surface of the container body 102. The jacket 110b′ may comprise a fluoropolymer material such as fluorinated ethylene propylene (FEP) and/or perfluoroalkoxy alkane (PFA).
[0106] The jacket 110b′ can act to provide a smooth, continuous sealing surface for contacting the inner surface of the container 102. It will be appreciated that this can allow the core 110a′ to be formed of a material and/or structure that would otherwise be unsuitable for sealing, e.g., a coiled spring.
[0107] Referring now to
[0108] The spring 110a″ can take the form of a continuous contact spring, a cantilever spring, a helical spring, or an elliptical coil. Alternatively, the spring 110a″ can be formed of a hollow or solid polymeric ring. A single spring 110a″ may be used to bias the sealing ring 110b″ in a radially outward direction, or a plurality of springs may be used to perform this function. The outer sealing ring 110b″ is advantageously formed of a material that is compatible with drug products and one that can provide low frictional engagement with an inner surface of the container 102. A suitable material for the outer sealing ring 110b″ may be elastomeric materials such as butyl rubbers, halogenated butyl rubbers or fluoropolymers such as FEP and PFA. The outer sealing ring may be further coated with an inert material, at least on a portion of its surface.
[0109] The configuration of the resilient portion(s) 110, 110′, 110″ described above is such that a temperature resilient seal may be formed between the plunger assembly and the container 102 so that the container assembly is operable to contain a medicament between the seal and the opening at: (a) room temperature (e.g. approximately 20° C.), and (b) during freeze storage of the medicament, with the plunger assembly still being movable relative to the container at room temperature.
[0110] Referring again to
[0111] Referring now to
[0112] The open fill container system further comprises a stopper assembly 220 configured to close the open (distal) end of the container 202, and an insert assembly 230 configured to maintain a minimum distance between the plunger assembly 206 and the second (proximal) end of the container 202. By providing an insert that limits the position of the plunger assembly, it is possible to improve control over placement of the plunger assembly with the container body, thus improving the accuracy with which the interior fill volume of the container can be defined.
[0113] As shown in
[0114] The end cap may be formed from one or more rigid polymeric materials, such as polyethylene (PE), polypropylene (PP), polyvinyl chloride (PVC), polystyrene (PS), polyethylene terephthalate (PET) or acrylonitrile butadiene styrene (ABS). Advantageously, the material chosen for the end cap is compatible with cryopreservation media such as dimethyl sulfoxide (DMSO).
[0115] The insert assembly 230 comprises an insert 232 at least partially disposed in the container 202 and configured to maintain a minimum distance between the plunger assembly 206 and the second (proximal) end of the container 202. The insert 232 is in turn held within the container body 202 by a second end cap 234. The second end cap 234 may be threadedly engaged with the container 202 by way of complementary screw threads provided on the container 202 and the second end cap 234. However, the second end cap 234 may also be snap fit over the container body, or otherwise engaged with the container body to maintain the insert 232 within the interior volume of the container 202, between the plunger assembly 206 and the second (proximal) end of the container. In this way, the insert 232 can act as a spacer between the second end cap 234 and the plunger 206, to ensure that a minimum distance between the plunger assembly 206 and the second (proximal) end of the container 202. Moreover, frangible connections between the end cap and the container may also be used to help ensure that the container is used only once.
[0116] As will now be described with reference to
[0117] For example, as shown in
[0118] In a second configuration shown in
[0119] In a third configuration, the insert assembly can comprise an end cap and insert configured for snap-fit engagement with each other (or another form of selective engagement).
[0120] For example, as shown in
[0121] The insert assembly (or at least one portion thereof) may be formed from one or more rigid polymeric materials, such as polyethylene (PE), polypropylene (PP), polyvinyl chloride (PVC), polystyrene (PS), polyethylene terephthalate (PET) or acrylonitrile butadiene styrene (ABS). Advantageously, the material chosen for the insert assembly is compatible with cryopreservation media such as dimethyl sulfoxide (DMSO).
[0122] Referring now to
[0123] As shown in
[0124] The stopper 322 comprises a generally cylindrical body 322a, configured to sit within a neck of container 302. The stopper 322 also comprises a flange 322b, extending in a radial direction from the generally cylindrical body 322a, which abuts a rim surrounding the opening of the container 302. The cylindrical body 322a comprises an outer surface 322c. The generally cylindrical body 322a can be closed at the first end (the end comprising the flange 322b), and open at the opposing second end. In this way, the stopper 322 can comprise a septum portion 322d through which access to the interior volume of the container 302 may be accessed e.g., by a needle piercing the septum 322d.
[0125] The stopper 322 comprises a groove 312, which extends around the outer surface 322c of the generally cylindrical portion 322a. The groove 312 at least partially receives a resilient sealing portion 310. As shown in
[0126] The sealing portion 310 can take the form of an O-ring, similar to the O-ring 110′ described above. The O-ring 310 can have a thickness (in the radial direction) that is greater than or equal to the depth of the groove, such that an outer sealing surface of the O-ring extends radially to a distance that is greater than or equal to the outer surface of the generally cylindrical body 322a. In this manner, the O-ring can provide an interference fit with an inner surface of the container 302 to maintain a seal between the stopper 322 and the container 302.
[0127] The O-ring 310 can be an encapsulated O-ring consisting of two parts: a core material and a jacket that at least partially encapsulates the core material. The construction of the O-ring 310 can be the same or similar as the construction shown in cross-section in
[0128] The core may be monolithic (formed as a single piece) or may comprise multiple connected resilient components.
[0129] The jacket, which partially or wholly encapsulates the core, can comprise an inert material (compatible with drug products) and/or one that can provide low frictional engagement with the inner surface of the container body 302. The jacket may comprise a fluoropolymer material such as fluorinated ethylene propylene (FEP) and/or perfluoroalkoxy alkane (PFA).
[0130] The jacket can act to provide a smooth, continuous sealing surface for contacting the inner surface of the container 302. It will be appreciated that this can allow the core to be formed of a material and/or structure that would otherwise be unsuitable for sealing, e.g., a coiled spring.
[0131] The resilient sealing portion 310 may also take the form of a spring energised seal, for example, constructed according to the configuration described above with reference to
[0132] In this configuration, the spring can take the form of a continuous contact spring, a cantilever spring, a helical spring, or an elliptical coil. A single spring may be used to bias the sealing ring in a radially outward direction, or a plurality of springs may be used to perform this function. The outer sealing ring is advantageously formed of a material that is compatible with drug products and one that can provide low frictional engagement with an inner surface of the container. A suitable material for the outer sealing ring may be elastomeric materials such as butyl rubbers, halogenated butyl rubbers or fluoropolymers such as FEP and PFA.
[0133]
[0134] As shown in
[0135] The stopper 422 is held in place by an end cap 424. The end cap 424 can be a crimped seal, a snap-fit cap, or other cap assembly configured to hold the stopper 422 in place within a neck of a container 402.
[0136] The stopper assembly 420 of
[0137] The resilient sealing portion 410 can comprise an O-ring or a spring energised seal, similar to the resilient portions 110, 110′, 110″ and 310 described above. In this configuration, by providing an O-ring or spring energised seal comprising a core material and (at least a partial) outer jacket, the core material can be chosen to minimise thermal expansion and/or contraction of the resilient portion(s), whilst the jacket material can be chosen to form a suitable seal with a sealing surface of a syringe barrel or vial flange.
[0138] The configuration of the resilient sealing portion(s) 310, 410 described above is such that a temperature resilient seal may be formed between the stopper assembly and the container so that the container assembly is operable to contain a medicament between the seal and the opening at: (a) room temperature (e.g. approximately 20° C.), and (b) during freeze storage of the medicament, with the plunger assembly still being movable relative to the container at room temperature.
[0139] Referring again to
[0140] Moreover, although the stopper assemblies of
[0141] Operation of the container assembly described with reference to
[0142] As shown in
[0143] Turning to
[0144]
[0145]
[0146] To allow medicament M to be delivered from the container 202, the first end of the container 202 is configured to be coupled to a delivery conduit. The delivery conduit may take the form of a delivery conduit hub 244 and flexible delivery conduit 246 configured to deliver medicament to a patient via e.g., an infusion set. Alternatively, the delivery conduit may take the form of a delivery conduit hub 244′ and a needle 246′ via which a medicament M can be injected into a patient.
[0147] In either case, the delivery conduit hub 244, 244′ can be configured to pierce a septum of the stopper assembly 220 to establish fluid communication between the delivery conduit (e.g., tube 246, or needle 246′) and the interior volume of the container 202 containing medicament M.
[0148] Although
[0149] Turning now to
[0150] As shown in
[0151] The vented cap 554 comprises at least one, and optionally two or more openings 556 configured to allow air to pass into (and out of) of the container 502 through the opening(s) 556. A filter 552 extends across the opening(s) 556 to prevent the ingress of particulates into the container 502. The filter 552 may be, for example, a 0.22 μm filter.
[0152] The vented cap assembly 550 shown in
[0153] As will now be described with reference to
[0154] For example, in a first arrangement (shown in
[0155]
[0156] Turning to
[0157]
[0158] As shown in
[0159] Turning now to
[0160] In the arrangement shown in
[0161] In an alternative embodiment, the vented cap assembly 550 may further comprise a hollow insert, similar to the previously described insert 232, except that the hollow insert of the vented cap assembly 550 would be hollow and have two open ends to allow air to pass through the hollow insert. In another embodiment, the hollow insert and the vented cap 554 may be monolithic (formed as a single piece), so that removing the vented cap 554 would simultaneously remove the hollow insert. In such an embodiment, the filter 552 would be embedded within the monolithic component. In a preferred embodiment, the hollow insert and vented cap 554 may be provided as separate components, but provided with a coupling, such as a snap-fit, so that the two components may be attached to capture the filter between the two components.
[0162] The vented end cap and/or hollow insert may be formed from one or more rigid polymeric materials, such as polyethylene (PE), polypropylene (PP), polyvinyl chloride (PVC), polystyrene (PS), polyethylene terephthalate (PET) or acrylonitrile butadiene styrene (ABS). Advantageously, the material chosen for the vented end cap is compatible with cryopreservation media such as dimethyl sulfoxide (DMSO).
[0163] The filter may be formed from paper, cellulose, nylon, polycarbonate, polyvinylidene fluoride, polypropylene, polyethersulfone, polytetrafluoroethylene, mixed cellulose esters, and others.
[0164] A check valve 560 is provided at the first end of the container 502 and is configured to allow the flow of fluid into the container 502. The check valve can be a one-way bicuspid valve, but other types of one-way valve can also be used. In at least some configurations, the valve 560 comprises silicone.
[0165] The valve 560 can be co-moulded with the container 502. A co-moulded valve can be particularly advantageous for continuity of sterility and ease-of-use, but it will be appreciated that the valve 560 may also be formed separately and disposed within the container 502. The check valve may be formed of the same material as the body of the container. Alternatively, the check valve can be a separate sub-assembly made from one or more rigid polymeric materials, such as polyethylene (PE), polypropylene (PP), polyvinyl chloride (PVC), polystyrene (PS), polyethylene terephthalate (PET) or acrylonitrile butadiene styrene (ABS). Advantageously, the material chosen for the check valve is compatible with cryopreservation media such as dimethyl sulfoxide (DMSO).
[0166] In some configurations, a check valve can be configured to operate in the opposite flow direction to the check valve 560 (e.g., to allow flow out of the container 502) when engaged with a complementary vial adapter. A possible vial adapter configuration will be described in more detail with reference to
[0167] The container assembly 500 can be supplied with a valve adapter 580. The valve adapter 580 can comprise a housing 582 configured to engage the first end of the container 502. The housing 584 comprises a valve engagement portion 582, for example a needle or probe, which can be inserted into the valve 560 and is configured to allow flow through the valve 560 in a direction out of the container 502 (i.e., in a direction opposite the direction of flow allowed through the valve 560 without the adapter in place). The valve engagement portion 582 is configured to provide fluid communication between the valve 560 and a conduit 586. Via the valve adapter 580, medicament can therefore be discharged from the container 502 through the valve 560 located at the first end. This configuration may be advantageous because it can allow easier filling of the container, with the one-way valve preventing the leakage of fluid from the container once filled.
[0168] In the event that the check valve 560 is configured to allow one-way flow out of the container 502, the valve adaptor 580 can be configured to open the valve 560 to allow the flow of fluid through the valve 560 into the container via the valve adaptor 580.
[0169] Filling of the container 502 will now be described in more detail with reference to
[0170] As shown in
[0171] To allow the container 502 to be filled, the valve adapter 580 is secured to the first end of the container 502, such that the valve engagement portion 582 establishes fluid communication between the conduit 586 and the internal volume of the container 502. In this way, medicament can be introduced into the container 502 through the valve adaptor 580.
[0172] Turning now to
[0173]
[0174] The valve cover 530 is also removed, from the first end of the container. Removal of the valve cover 530 allows access to the check valve 560. Although not shown in the drawings, it will be appreciated that the first end of the container 502 can be configured to mate with a hub that provides fluid communication to a delivery conduit. The delivery conduit can take the form of a needle or a flexible conduit through which medicament M can be delivered. The check valve 560 can ensure that medicament M can exit the container 502 via the check valve 560, but that the container 502 cannot be refilled without a valve adaptor 580.
[0175] Turning now to
[0176] In general terms, methods according to the disclosure include a method of filling a container assembly according to any of the configurations described above. For example, the container assembly can comprise (i) a container having a first end and a second end, the first end comprising a first opening; and (ii) a plunger assembly at least partially disposed in the container. The plunger assembly can comprise: (i) a main body; and (ii) at least one resilient portion at least partially retained by a groove in the main body and forming a seal with the container. The plunger assembly is configured to form a temperature resilient seal with the container such that the container assembly is operable to contain a medicament between the seal and the first opening at: (a) room temperature, and (b) during freeze storage of the medicament; and be moveable relative to the container at room temperature. The method of filling the container described above includes the step of filling the container assembly with the medicament via the opening in the first end. After filing the container assembly with the medicament, an optional step of freezing the medicament contained in the container assembly may also be performed. The freezing step can comprise cooling the contents of the container to between −50° and −200° C. This method can further comprise the step of sterilising the container assembly, before or after filling the container.
[0177] In addition to a method of a container assembly to provide a pre-filled assembly, the present disclosure also provides methods of forming (and optionally filling) the containers described above.
[0178]
[0179] At step 606, the second end of the container is closed with an end cap. A spacing insert is optionally provided between the plunger assembly and the end cap to maintain a pre-defined minimum distance between the second end of the container and the plunger assembly.
[0180] At step 608, the container is filled with a medicament. Note that the order of steps 606 and 608 may be reversed so that the container is filled with medicament before the end cap is positioned to close the second end of the container. The medicament M is introduced into the space defined between the plunger assembly and the first end of the container.
[0181] At step 610, after the filling step, the first end of the container is closed with a stopper. A first end cap may be positioned over the stopper to maintain the stopper in place over the first end of the container. Once the first end of the container is closed with the stopper, the medicament M is sealed within the container.
[0182] Optionally, at step 612, the medicament is frozen. The medicament may be frozen by reducing its temperature to below 0° C., optionally between −50° C. and −200° C. This method can further comprise the step of sterilising the container assembly, before or after filling the container.
[0183]
[0184] At step 706, the first end of the container is closed with a check valve. At step 708, the second end of the container is closed with a vented end cap. A filter may be provided between the vented end cap and the second end of the container during this step.
[0185] The order of steps 706 and 708 may be reversed so that the vented end cap is positioned before the check valve. Moreover, in at least some embodiments, the check valve is co-moulded with the container so steps 702 and 706 happen substantially simultaneously.
[0186] The method of manufacturing a container assembly may end after step 708, and the container assembly may be provided to a user in an empty state. However, the method may also comprise optional filling and/or freezing steps, as will be described below.
[0187] At step 710, the container is filled with a medicament. The medicament may be introduced into the container through the check valve. A valve adaptor may or may not be used for this step, depending on the permitted flow direction of the check valve. The filling step drives the plunger assembly from its initial position at the first end of the container (adjacent the check valve) towards the second end of the container. In this way, the medicament M is introduced into a space defined between the plunger assembly and the first end of the container.
[0188] After step 710, the medicament is optionally frozen. The medicament may be frozen by reducing its temperature to below 0° C., and optionally between −50° C. and −200° C. This method can further comprise the step of sterilising the container assembly, before or after filling the container.
[0189] Although, the present disclosure describes plunger assemblies configured to maintain a seal at very low temperatures in the context of exemplary container assemblies, it will be appreciated that the present disclosure also provides plunger assemblies in isolation from the wider container assembly.
[0190] In one aspect of the disclosure, a plunger assembly comprises a main body; and at least one resilient portion at least partially retained by a groove in the main body. The resilient portion is configured to form a seal with a container for containing a medicament. The plunger assembly is further configured to: form a temperature resilient seal with a container such that the container assembly is operable to contain a medicament between the seal and a first opening of the container at: (a) room temperature, and (b) during freeze storage of the medicament; and to allow movement of the plunger assembly relative to the container at room temperature.
[0191] The plunger assembly can take the form of the plunger assemblies described with reference to
[0192] Similarly, although the present disclosure describes stopper assemblies configured to maintain a seal at very low temperatures in the context of exemplary container assemblies, it will be appreciated that the present disclosure also provides stopper assemblies in isolation from the wider container assembly.
[0193] In one aspect of the disclosure, a stopper assembly is provided that is configured to seal an opening of a container. The stopper assembly comprises a stopper configured to be at least partially disposed in the opening of a container for containing a medicament. The stopper assembly also comprises at least one resilient sealing portion at least partially retained by the stopper and configured to form a seal with the container.
[0194] The stopper can comprise a generally cylindrical body having an outer surface comprising at least one groove, and wherein the at least one resilient sealing portion is at least partially retained by the at least one groove.
[0195] The stopper assembly can take the form of the assemblies described with reference to
[0196] The preceding detailed description describes container assemblies, and associated systems and methods that are configured to maintain a seal at cryogenic temperatures, and also allow movement of a plunger within the system at room temperature. However, the skilled person will understand that the invention is not limited to use in connection with the exemplary device described here. Rather, one or more benefits associated with the present invention may be implemented in connection with other drug delivery systems, as will be apparent to the skilled person in light of the preceding detailed description.
[0197] It will also be understood that, where used, the terms “proximal”, “distal”, “front”, “back”, “side”, “top” and “bottom” are used for convenience in interpreting the drawings and are not to be construed as limiting. The term “comprising” should be interpreted as meaning “including but not limited to”, such that it does not exclude the presence of features not listed.
[0198] The embodiments described and shown in the accompanying drawings above are provided as examples of ways in which the invention may be put into effect and are not intended to be limiting on the scope of the invention. Modifications may be made, and elements may be replaced with functionally and structurally equivalent parts, and features of different embodiments may be combined without departing from the disclosure.